AUTHORS
Brett Matzuka, Anasuya Hazra, PhD2, Robert Orlowski, MD, PhD3, Christopher J. Ferreri4, Anita Boyapati, PhD5, Steven Quatela6, John D. Davis7, Lutz Harnisch8, Jason Chittenden9
AFFILIATIONS
1 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
2 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
5 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
6 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
7 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
8 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
9 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
ABSTRACT
Introduction
Linvoseltamab is a human B-cell maturation antigen (BCMA)×CD3 bispecific antibody that demonstrated deep, durable responses, and generally manageable safety as monotherapy in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in the Phase 1/2 LINKER-MM1 study (NCT03761108). Linvoseltamab, administered via intravenous infusion, is approved at a full dose of 200 mg for triple-class exposed RRMM after ≥3 prior therapies (EU) or ≥4 prior lines of therapy (USA). The Phase 1/2 LINKER-MM4 study (NCT05828511) is investigating linvoseltamab monotherapy in both transplant-eligible and -ineligible pts with newly diagnosed multiple myeloma (NDMM), who are treatment-naïve. Here, we report the pharmacokinetics (PK) of linvoseltamab and characterize the relationships between linvoseltamab exposure, disease burden biomarkers, and clinical response endpoints using data from Phase 1. A semi-mechanistic population PK/pharmacodynamic (popPK/PD) model and exposure–response analyses evaluated the impact of linvoseltamab exposure on biomarker dynamics and efficacy, providing a quantitative framework to support dose selection and ongoing clinical development in NDMM.
Methods
In Phase 1 of LINKER-MM4, pts received linvoseltamab using a step-up regimen (1 mg, Day 1; 4 mg, Day 4; 25 mg, Day 8), followed by full dose at three dose levels (50, 100, or 200 mg) on Day 15, then weekly or every 2 weeks; pts receiving 200 mg transitioned to dosing every 4 weeks after ≥24 weeks if they reached at least very good partial response. Total linvoseltamab, soluble BCMA (sBCMA), and free light chain (FLC) concentrations were measured using serum samples collected throughout treatment, and PK parameters summarized descriptively. A popPK/PD model incorporating multiple myeloma subtype and baseline sBCMA and total FLC concentrations captured initial disease burden and enabled prediction of exposure in a simulated NDMM population (N=5000). Model-predicted free linvoseltamab concentrations were used in an exposure–response analysis of objective response rate (ORR) and biochemical progression-free survival (bPFS, time without disease progression based on biochemical components of International Myeloma Working Group criteria, including FLC concentrations), assessing the 50 and 200 mg doses.
Results
PK samples (cut-off date: May 28, 2025) were collected from 45 pts treated at doses of 50 (n=20), 100 (n=4), and 200 mg (n=21). Linvoseltamab concentration–time profiles and PK parameters showed consistent, dose-dependent exposure with generally moderate interpatient variability. In disease biomarker analyses, linvoseltamab treatment resulted in pronounced and persistent reductions in sBCMA concentrations across dose levels; by Day 85, total sBCMA was reduced to levels approximating those observed in healthy individuals (<30 ng/mL; Wiedemann Á, et al. Pathol Oncol Res 2023). Reductions in involved FLC and monoclonal protein concentrations were generally consistent with sBCMA findings, and indicated a rapid decrease in disease burden that persisted throughout treatment. Transient inductions in cytokine (interleukin [IL]-2, interferon-γ, IL-6) concentrations were observed post-linvoseltamab infusion, with the highest elevations observed during step-up dosing.
Exposure–response analysis included 41 pts treated at full doses of 50 mg (n=20) and 200 mg (n=21). In population simulations, at the end of infusion, treatment responders (partial response or better) in both groups had higher median free linvoseltamab concentrations than nonresponders: 200 mg, 0.0608 (5th–95th percentile, 0.0026–16.7; n=16) vs 0.00758 (0.00438–0.499; n=5) mg/L; 50 mg, 0.122 (0.0149–2.46, n=14) vs 0.00713 (0.00166–0.0316, n=6) mg/L. Predicted median free linvoseltamab concentrations at the end of infusion after the first full dose were approximately 3.5-fold higher with the 200 mg dose than with the 50 mg dose (0.0431 vs 0.01241 mg/L, respectively). Simulations predicted higher 1-year bPFS with the 200 mg versus 50 mg dose (78.9% vs 72.3%), and the superior ORR observed with the 200 mg versus 50 mg dose (85.7% vs 70.0%) further supported the results of the exposure–response model.
Conclusions
This comprehensive evaluation of PK, biomarker dynamics, and exposure–response relationships, in addition to the manageable safety profile previously reported (Orlowski RZ, et al. Blood 2025), supports selection of the 200 mg dose of linvoseltamab for further development in pts with NDMM.
DISCLOSURES
Brett Matzuka: Regeneron Pharmaceuticals, Inc. - Current equity holder in publicly-traded company; Regeneron Pharmaceuticals, Inc. - Stock (publicly traded); Regeneron Pharmaceuticals, Inc. - Current Employment